The purpose of this study was to evaluate the effectiveness of a new formulation of ibuprofen (ibuprofen-arginine [IA]) in the treatment of migraine attacks. This is a faster absorbed formulation as compared with ibuprofen alone. The rapidity of action is considered to be a crucial factor in the treatment of migraine attacks. Forty migraine patients participated in this multicenter, double-blind, crossover, randomized, placebo-controlled trial. Each patient was treated with a single oral dose of IA 400mg or placebo during two consecutive migraine attacks. The results confirm the efficacy of IA, with a significant (p <0.05) improvement in pain relief at 30 minutes after treatment. A statistically significant (p <0.001) reduction in pain intensity was observed at 1, 2, 4, and 6 hours after treatment with ibuprofen as compared with placebo. IA was well tolerated and this data indicate that this new formulation of ibuprofen is valuable in the treatment of acute migraine attacks.
|Number of pages||1|
|Publication status||Published - 1999|
ASJC Scopus subject areas
- Clinical Neurology